Position in ARVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$23,234,760
+$2,267,960 QoQ
Shares Held
2,796,000
+41.4% QoQ
Ownership
4.28%
of shares outstanding
% of Portfolio
0.64%
of 13F equity value
Holder Rank
#5
of 198 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARMISTICE CAPITAL, LLC holds $1,506,954,940 across 50 Biotechnology names. ARVN ranks #22 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
288,000 | $154,641,600 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,201,342 | $102,342,324 | |
| 3 | INCY |
Incyte Corp
|
900,005 | $102,024,566 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
1,572,539 | $89,335,940 | |
| 5 | AGIO |
Agios Pharmaceuticals, Inc.
|
2,400,000 | $89,064,000 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
1,071,395 | $87,393,690 | |
| 7 | DYN |
Dyne Therapeutics, Inc.
|
3,087,226 | $68,567,289 | |
| 8 | IMVT |
Immunovant, Inc.
|
1,736,000 | $66,888,080 |
All Filings in ARVN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23,234,760 | 2,796,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $20,966,800 | 1,978,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $21,348,000 | 1,800,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $10,224,000 | 1,200,000 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $4,121,600 | 560,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||